Company intelligence / Profile preview

Becanex

Berlin Friedrichshain / Adlershof, Berlin, Germanyeu-startups.com ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Becanex has developed a patented One-Step extraction process to produce plant-identical full-spectrum cannabinoid extracts with high terpene diversity. The company transitioned to the medical cannabis market in 2023 and offers both full-spectrum and THC-free broad-spectrum CBD oils. Clinical results are not yet published; products are available commercially in food/cosmetics sectors while pharmaceutical development continues.

Therapeutic areas: OtherNeurology
Modalities: Small molecule (cannabinoids such as CBD, CBG, CBC)Plant extract
Industry: Biotech

Drug pipeline

3 assets

PIEX

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

Phytonext (technology partner)

Beyond the preview

Go deeper on Becanex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Becanex.

Explore the full profile